2 completed, 2 not yet recruiting, 1 active not recruiting, 1 recruiting. 2 Phase 2, 2 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 4 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Gout and Hyperuricemia: new trials by email Literature Review of Gout and Hyperuricemia trials Research Report on Gout and Hyperuricemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial Empagliflozin 10 mg, Placebo - Gout and Hyperuricemia | Phase 4 | Recruiting | Massachusetts General Hospital | 60 | 2026-07-01 | 2026-08-05 |
| Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia BR2251, Febuxostat - Gout and Hyperuricemia | Phase 2 | Not yet recruiting | BioRay Pharmaceutical Co., Ltd. | 160 | 2026-04-01 | 2026-03-27 |
| HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat - Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis | Phase 4 | Not yet recruiting | Haiphong University of Medicine and Pharmacy | 228 | 2026-01-20 | 2026-01-27 |
| PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval repaglinide; midazolam; SHR4640, repaglinide; midazolam; SHR4640; SHR4640 placebo, repaglinide; midazolam; SHR4640 placebo - Gout and Hyperuricemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2024-01-04 | 2024-03-06 |
| Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia RDEA3170, Allopurinol, Placebo - Gout and Hyperuricemia | Phase 2 | Completed | AstraZeneca | 204 | 2014-01-05 | 2019-09-24 |
| Long-Term Risk of Gout in Living Kidney Donors Living kidney donation - Living Kidney Donation, Living Kidney Donor | Active not recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 50000 | 1992-07-01 | 2026-09-14 |
Gout (6) · Hyperuricemia (6) · Arthritis, Gouty (1) · Stevens-Johnson Syndrome (1)
Arthritis (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Crystal Arthropathies (6) · Genetic Diseases, Inborn (6) · Joint Diseases (6) · Metabolic Diseases (6) · Metabolism, Inborn Errors (6) · Musculoskeletal Diseases (6) · Nutritional and Metabolic Diseases (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Purine-Pyrimidine Metabolism, Inborn Errors (6) · Rheumatic Diseases (6) · Chemically-Induced Disorders (1) · Dermatitis (1)
Allopurinol (2) · Febuxostat (2) · Midazolam (1) · empagliflozin (1) · repaglinide (1) · ruzinurad (1) · verinurad (1)
AstraZeneca (1) · BioRay Pharmaceutical Co., Ltd. (1) · Haiphong University of Medicine and Pharmacy (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Massachusetts General Hospital (1)
China (1) · Japan (1) · United States (1)
R61AR084188 (1)